Oncocyte CORP 8-K filings
Oncocyte announced its first quarter 2024 financial results, highlighting a new partnership with Bio-Rad, progress in commercializing its GraftAssure test, and a reduction in cash burn.
8-K: Oncocyte Secures $15.8 Million in Private Placement to Bolster Operations and Redeem Preferred Stock
Oncocyte Corporation has successfully raised $15.8 million through a private placement to fund operations and redeem outstanding preferred stock.
Oncocyte Corporation and Bio-Rad Laboratories have entered into a collaboration agreement to commercialize Oncocyte's transplant monitoring assays, with Bio-Rad making an equity investment and gaining global distribution rights.
Oncocyte Corporation has officially launched its VitaGraft Kidney test, a blood-based assay for monitoring kidney transplant patients, making it broadly available after an early access program.